"MicroGen Synthesis" completes 300 million yuan Series A+ funding, jointly launching an open collaboration platform for AI biological computing

DeepFlowTech · 2026-03-30T05:39:55+00:00

WeiYuan completed a 300 million RMB Series A+ funding round in March 2026, with the funds used to expand AI biological computing and technological research and development. At the same time, they jointly launched the PoseX platform with multiple institutions to address molecular docking challenges. The company has developed several products and is also focusing on methanol biomanufacturing.

DeepFlowTech

2026-03-30 05:39:55

Abstract generation in progress

According to TechFlow news on March 30, 36Kr reported that the synthetic biotechnology developer MicroGenetics completed a 300 million yuan A+ round of financing in March 2026, with investment from Henan Investment Group Huirong Fund and Mr. Tan Ruiqing. This round of financing will be used to broaden the boundaries of AI bio-computing applications and increase investment in core technology R&D and scenario implementation.

At the same time, MicroGenetics, in collaboration with Stanford University, Princeton University, Peking University, ByteDance, NVIDIA, and other institutions, launched the open collaboration platform PoseX at ICLR 2026, aimed at solving the molecular docking challenges in real-world scenarios and systematically evaluating 24 mainstream methods. Test results show that top AI docking methods (such as SurfDock) and co-folding methods (such as AlphaFold3) have fully surpassed traditional physical models in accuracy and robustness for cross-conformation docking tasks.

Currently, MicroGenetics has completed the R&D and commercialization of several products including alditol, lutein, and mannitol, and is accelerating the layout of product lines related to methanol biomanufacturing.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes